Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

Treatment with cytarabine and daunorubicin (7 + 3 ... Several potential causes have been identified, including infections, elevated levels of IL-2, granulocyte colony-stimulating factor (G-CSF) ...

Denileukin diftitox is under clinical development by Citius Oncology and currently in Phase II for Endometrial Cancer.

Denileukin diftitox is under clinical development by Citius Oncology and currently in Phase II for Non-Small Cell Lung Cancer.

29, 1984, he infused these back into her bloodstream and inoculated her with higher than typical doses of IL-2 repeatedly, hoping to put her immune system into overdrive. The treatment was difficult.

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

that are typically associated with wild-type IL-2 treatment. Furthermore, the ability of STK-009 to provide an IL-2 signal exclusively to SYNCAR-001 cells may allow us to bypass the need for ...

1 Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China 2 Institute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, ...

The drug, SAR444245, is part of an emerging class of cancer immunotherapies based on interleukin-2 (IL-2). This cytokine is a protein that coaxes a powerful immune response against cancer cells.

Another illustration of an agent developed at a high dose for cancer treatment which was subsequently pursued at a low dose for immune-mediated diseases is the cytokine interleukin-2 (IL-2).